Insilico’s AI-designed oncology candidate: a news piece previewing regulatory progress, trial updates and how AI shaped its development path.
Key Takeaways
- ISM6331 received FDA Fast Track Designation for advanced unresectable malignant pleural mesothelioma treatment
- ISM6331 previously received Orphan Drug Designation and began dosing patients in a global Phase I trial
- Insilico engineered ISM6331 with its Chemistry42 AI platform and reported initial Phase I data accepted for ESMO 2026